Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
Author(s) -
Ivan N. Mefford,
J. Tyler Mefford,
Colleen Burris
Publication year - 2012
Publication title -
case reports in endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.26
H-Index - 6
eISSN - 2090-6501
pISSN - 2090-651X
DOI - 10.1155/2012/468609
Subject(s) - medicine , neogenesis , omeprazole , endocrinology , hemoglobin , type 2 diabetes , diabetes mellitus , insulin , gastrin , oral administration , islet , secretion
A 43-year-old man with type 2 diabetes, opposed to insulin use and poorly responsive to oral agents added sequentially over 6 years, was placed on 40 mg omeprazole twice daily. A linear decline in daily fasting blood glucose was observed over the first two-month treatment, and his hemoglobin A1c was reduced from 11.9% to 8.2%, then sustained at 8.1% after four months. Glucose, insulin, and C-peptide response to a 2-hour glucose tolerance test were consistently improved across this time period, and calculated beta-cell mass increased by 67%. We believe these responses are consistent with activation or neogenesis of pancreatic beta cells, possibly through a gastrin-mediated mechanism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom